The FDA has approved Tivicay PD dispersible tablets for combination HIV-1 treatment in full-term neonates weighing at least 2kg.

Interim Phase 1b/2a trial data support the MKK4 inhibitor's potential to protect hepatocytes and accelerate liver regeneration following surgical resection.

Phase 3 RASolute 302 data show daraxonrasib significantly extended overall and progression free survival compared with ...

Clinicians may not agree on physical exam findings for youth with community-acquired pneumonia (CAP), according to a study published online August 20 in JAMA Ne ...

HealthDay News — For patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), the combination of anastrozole, palbociclib, ...

Imaavy (nipocalimab-aahu) is the first FcRn blocker approved to treat warm autoimmune hemolytic anemia in patients aged 12 years and older.

Interim phase 2 AZUR-1 trial results demonstrating sustained 12-month clinical complete responses support the priority review submission.

The FDA has approved two Ziihera (zanidatamab-hrii) regimens for first-line HER2-positive advanced gastroesophageal adenocarcinoma, offering significant survival gains over trastuzumab-based therapy.

One phlebotomist can oversee up to 3 Aletta machines, directly helping to address the current phlebotomist shortage and long ...

Significantly lower all-cause infection rate seen in children receiving daily zinc supplementation versus placebo ...

Investigational siRNA therapeutic targeting prekallikrein receives FDA Fast Track designation following promising phase 1/2 data in HAE.

The FDA requires an additional 3 months to review a major amendment to the Biologics License Application for deramiocel, ...